BeOne Medicines Ltd. - Sponsored ADR (ONC)
(Real Time Quote from BATS)
$296.39 USD
-10.84 (-3.53%)
Updated Aug 6, 2025 01:30 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ONC 296.39 -10.84(-3.53%)
Will ONC be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ONC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ONC
BeOne Medicines Ltd. - Sponsored ADR (ONC) Reports Q2 Earnings: What Key Metrics Have to Say
Stevanato (STVN) Soars 10.0%: Is Further Upside Left in the Stock?
ONC: What are Zacks experts saying now?
Zacks Private Portfolio Services
BeOne Medicines Ltd. - Sponsored ADR (ONC) Surges 4.0%: Is This an Indication of Further Gains?
Compared to Estimates, BeiGene (ONC) Q1 Earnings: A Look at Key Metrics
Community Health Q1 Earnings Top on Rising Patient Volumes, Stock Up 8%
Other News for ONC
BeOne Medicines beats top-line and bottom-line estimates; updates FY guidance
ONC Reports Q2 Revenue Surpassing Expectations, Reinforcing Growth Trajectory
ONC Reaffirms FY25 Financial Outlook with Steady Revenue and Expenses
BeOne Medicines Ltd Q2 2025 Earnings: EPS of $0.84 Beats Estimate, Revenue Surges to $1.3 Billion
BeOne Medicines narrows FY25 revenue view to $5.0B-$5.3B from $4.9B-$5.3B